AGENT: An open-label phase III study of arfolitixorin versus leucovorin in modified FOLFOX-6 for first-line treatment of metastatic colorectal cancer-MedSci.cn

AGENT: An open-label phase III study of arfolitixorin versus leucovorin in modified FOLFOX-6 for first-line treatment of metastatic colorectal cancer

Lenz, HJ; Gibbs, P; Stintzing, S; Prager, GW; Nygren, P; Papadimitriou, CA; Tell, R; Yoshino, T; Jonker, DJ; De Gramont, A; Tabernero, J

JOURNAL OF CLINICAL ONCOLOGY, 2020; 38 (4):

科室
- - 订阅+
  - 更多科室
工具
服务